Monte Rosa Therapeutics, Inc. (“Monte Rosa,” “MRT” or the “Company”) is a biopharmaceutical company developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade disease-causing proteins. The Company has developed a proprietary protein degradation platform, called QuEEN, that enables MRT to identify protein targets and molecular glue degrader (MGD) drug candidates that can eliminate disease-causing proteins. Lead product candidate, MRT-1577, is an oral MGD that selectively targets GSPT1, a G-loop degron-containing neosubstrate that has been identified as a potential target in oncology.